Health
Rheumatoid arthritis drug tied to fewer deaths in COVID patients – CIDRAP
In both studies, patients receiving tocilizumab had about half the risk of dying.
Two new studies have revealed that the rheumatoid arthritis drug tocilizumab is associated with lower death rates in COVID-19 patients receiving mechanical ventilation. Tocilizumab blocks interleukin-6 (IL-6), an inflammatory protein involved in a potential “cytokine storm” that can lead to respiratory failure in coronavirus patients.
In the first single-center observational study, published late last week in Clinical Infectious Diseases, University of Michigan at Ann Arbor researchers found that tocilizumab was linked to a 45% reduction in risk of death (hazard ratio
-
Noosa News21 hours agoPrincess Anne is coming to Australia. Here’s what we know of her plans
-
General11 hours agoDeepfake AI ad featuring WA Premier Roger Cook prompts latest scam warning
-
General10 hours agoCommunity devastated after freight train kills one-year-old girl near Narrabri
-
General8 hours agoPolice allowed neo-Nazi protest outside NSW parliament